Skip to main content
. Author manuscript; available in PMC: 2007 Mar 19.
Published in final edited form as: Pharmacol Ther. 2005 Jun;106(3):357–387. doi: 10.1016/j.pharmthera.2005.01.001

Table 3.

Endogenous FMO substrates

Substrate FMO Km (μM) Product Reference
Sulfur-containing
Cysteamine pFMO1a 120 Disulfide Poulsen, 1981
hFMO2 175 Unpublished
S-cysteine conjugates pFMO1 344–1538 S-oxide (diastereometric excess 10–78%) Park et al., 1992
S-allyl-l-cysteine Rat in vivo Sulfoxide Krause et al., 2002
S-farnesylcysteine and pFMO1 Park et al., 1994
S-farnesylcysteine methyl ester 23–34 S-oxide Park et al., 1994
Dihydrolipoic acid and pFMO1 1700 Taylor & Ziegler, 1987
Lipoic acid pFMO1 120 Taylor & Ziegler, 1987
hFMO2 71 Unpublished
Methionine hFMO3 20,000 (d>l)-sulfoxide Ripp et al., 1999
rat FMO3 3400 (d>l)-sulfoxide Krause et al., 1996
Rabbit FMO1 48,000 (d/l=1.5)-sulfoxide Duescher et al., 1994
Rabbit FMO2 30,000 (d/l=0.7)-sulfoxide
Rabbit FMO3 6500 (d/l=8)-sulfoxide
Nitrogen-containing
Trimethylamine hFMO3 28 N-oxide Lang et al., 1998
pFMO1 617 Sabourin & Hodgson, 1984
Mouse liver FMO 2340 Sabourin & Hodgson, 1984
a

p = Pig; h = human.